Sentinel lymph node biopsy for breast cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 5, 2001, Pages 347-357

  Bold, R J ^a   Schlieman, M ^a   Fahy, B N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER STAGING; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE;

EID: 0035217908     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801753354258     Document Type: Review

References (69)

1. Cancer statistics, 2000
2. Breast cancer and aging. Clinical implications
3. Adjuvant therapy for breast cancer
4. Technical details of intraoperative lymphatic mapping for early stage melanoma
5. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
6. Sentinel-lymph-node biopsy for breast cancer - Not yet the standard of care
7. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes
8. Sentinel lymph node biopsy and axillary dissection in breast cancer: Results in a large series
9. Lymphatic mapping in the treatment of breast cancer
10. Sentinel node biopsy in the staging of breast cancer
11. The sentinel node in breast cancer
12. Lessons learned from 500 cases of lymphatic mapping for breast cancer
13. Improved axillary staging of breast cancer with sentinel lymphadenectomy
14. Sentinel lymphadenectomy in breast cancer
15. The role of sentinel lymph node biopsy in breast cancer
16. Controversies in sentinel lymph node biopsy for breast cancer
17. Controlled introduction of the sentinel node biopsy in breast cancer in a multi-centre setting: The role of a coordinator for quality control
18. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer
19. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18
20. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer
21. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma
22. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer
23. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer
24. Comprehensive review of sentinel lymphadenectomy in breast cancer
25. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma
26. Sentinel node biopsy for patients with DCIS: A dangerous and unwarranted direction
27. Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?
28. Lymph node metastasis from ductal carcinoma in situ with microinvasion
29. Sentinel node biopsy in ductal carcinoma in situ patients
30. Sentinel node biopsy in breast cancer: An overview
31. Techniques for lymphatic mapping in breast carcinoma
32. Sentinel lymph node biopsy for breast cancer: A suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used
33. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: Results of a multi-institutional study
34. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy
35. Mammary lymphoscintigraphy with various radiopharmaceuticals in breast cancer
36. Unfiltered sulfur colloid and sentinel node biopsy for breast cancer: Technical and kinetic considerations
37. In search of the true sentinel node by different injection techniques in breast cancer patients
38. Factors affecting sentinel node localization during preoperative breast lymphoscintigraphy
39. Subareolar versus peritumoral injection for location of the sentinel lymph node
40. Dermal versus intraparenchymal lymphoscintigraphy of the breast
41. Learning curves and certification for breast cancer lymphatic mapping
42. Credentialing for breast lymphatic mapping: How many cases are enough?
43. The learning curve for sentinel node biopsy in breast cancer: Practical considerations
44. Implementation of new surgical technology: Outcome measures for lymphatic mapping of breast carcinoma
45. Sentinel node biopsy in breast cancer
46. Credentialing issues with sentinel lymph node staging for breast cancer
47. Revised consensus statement on guidelines for performance of sentinel lymphadenectomy for breast cancer
48. What constitutes adequate study of axillary lymph nodes in breast cancer?
49. Does clearing of axillary lymph nodes contribute to accurate staging of breast carcinoma?
50. Fat clearance method versus manual dissection of lymph nodes in specimens of rectal cancer
51. Micrometastatic nodal disease in breast cancer - The dilemma continues
52. Role of immunohistochemical detection of lymphnode metastases in management of breast cancer
53. Serial sectioning of sentinel nodes in patients with breast cancer: A pilot study
54. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma
55. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients
56. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma
57. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma
58. Clinical relevance of serial sectioning of sentinel nodes and the detection of micrometastatic nodal disease in breast cancer
59. The significance of breast cancer lymph node micrometastases
60. Systemic treatment after sentinel lymph node biopsy in breast cancer: Who, what, and why?
61. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma
62. Interim update of ACOSOG protocol Z0010: A prospective study of sentinel node and bone marrow micrometastases in women with clinical T1 or T2 N0 M0 breast cancer
63. Unusual aspects of breast cancer: Case 3, blue hives during lymphatic mapping for breast cancer
64. Anaphylaxis to patent blue dye during sentinel lymph node biopsy for breast cancer
65. Delayed-type allergy to technetium Tc 99m
66. Adverse reactions to technetium-99m colloids
67. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma
68. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
69. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer